^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    AiRuiKa (camrelizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Camrelizumab combined with trastuzumab and CapeOX in HER2-positive patients with advanced gastric cancer in the first-line setting: an single-arm, monocentric phase 2 trial

    Excerpt:
    ......
    Trial ID:
    ChiCTR2000039886
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2022
    Title:

    Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

    Published date:
    01/18/2022
    Excerpt:
    In this ongoing, single-arm, phase II study...with histopathologically diagnosed resectable HER2-positive gastric or GEJ adenocarcinoma who had clinical T3/N+ or higher stage. Neoadjuvant combination of SHR1210, transtuzumab and CAPOX is a safe and efficacious treatment option for patients with HER2-positive gastric or GEJ adenocarcinoma.
    Secondary therapy:
    CAPOX
    DOI:
    10.1200/JCO.2022.40.4_suppl.296
    Trial ID:
    NCT03950271